Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 177

1.

Iron overload and chelation therapy in myelodysplastic syndromes.

Temraz S, Santini V, Musallam K, Taher A.

Crit Rev Oncol Hematol. 2014 Jul;91(1):64-73. doi: 10.1016/j.critrevonc.2014.01.006. Epub 2014 Jan 24. Review.

PMID:
24529413
2.

Iron overload in myelodysplastic syndromes: diagnosis and management.

List AF.

Cancer Control. 2010 Jan;17 Suppl:2-8. Review.

PMID:
20125080
3.

Optimizing therapy for iron overload in the myelodysplastic syndromes: recent developments.

Leitch HA.

Drugs. 2011 Jan 22;71(2):155-77. doi: 10.2165/11585280-000000000-00000. Review.

PMID:
21275444
4.

Iron chelation therapy in myelodysplastic syndromes.

Fausel CA.

Am J Health Syst Pharm. 2010 Apr;67(7 Suppl 2):S10-4; quiz S16. doi: 10.2146/ajhp090654.

PMID:
20332500
5.

Toward resolving the unsettled role of iron chelation therapy in myelodysplastic syndromes.

Merkel DG, Nagler A.

Expert Rev Anticancer Ther. 2014 Jul;14(7):817-29. doi: 10.1586/14737140.2014.896208. Epub 2014 Mar 18. Review.

PMID:
24641787
6.

Iron overload in myelodysplastic syndromes.

Mahesh S, Ginzburg Y, Verma A.

Leuk Lymphoma. 2008 Mar;49(3):427-38. doi: 10.1080/10428190701843221. Review.

PMID:
18297518
7.

Iron chelation therapy in MDS: what have we learnt recently?

Schmid M.

Blood Rev. 2009 Dec;23 Suppl 1:S21-5. doi: 10.1016/S0268-960X(09)70006-2. Review.

PMID:
20116636
8.

Objectives of iron chelation therapy in myelodysplastic syndromes: more than meets the eye?

Pullarkat V.

Blood. 2009 Dec 17;114(26):5251-5. doi: 10.1182/blood-2009-07-234062. Epub 2009 Aug 26. Review.

9.

Management of transfusion-related iron overload in patients with myelodysplastic syndromes.

Shah J, Kurtin SE, Arnold L, Lindroos-Kolqvist P, Tinsley S.

Clin J Oncol Nurs. 2012 Jun;16 Suppl:37-46. doi: 10.1188/12.CJON.S1.37-46. Review.

10.

When is iron overload deleterious, and when and how should iron chelation therapy be administered in myelodysplastic syndromes?

Steensma DP, Gattermann N.

Best Pract Res Clin Haematol. 2013 Dec;26(4):431-44. doi: 10.1016/j.beha.2013.09.009. Epub 2013 Oct 1. Review. Erratum in: Best Pract Res Clin Haematol. 2014 Jun;27(2):e1.

PMID:
24507819
11.

The deleterious effects of iron overload in patients with myelodysplastic syndromes.

Dreyfus F.

Blood Rev. 2008 Dec;22 Suppl 2:S29-34. doi: 10.1016/S0268-960X(08)70006-7. Review.

PMID:
19059054
12.

Iron chelation therapy for patients with myelodysplastic syndrome.

Yeh SP, Yang YS, Yao CY, Peng CT.

Hemoglobin. 2009;33(5):339-45. doi: 10.3109/03630260903212654. Review.

PMID:
19814680
13.

Deferasirox for transfusion-dependent patients with myelodysplastic syndromes: safety, efficacy, and beyond (GIMEMA MDS0306 Trial).

Angelucci E, Santini V, Di Tucci AA, Quaresmini G, Finelli C, Volpe A, Quarta G, Rivellini F, Sanpaolo G, Cilloni D, Salvi F, Caocci G, Molteni A, Vallisa D, Voso MT, Fenu S, Borin L, Latte G, Alimena G, Storti S, Piciocchi A, Fazi P, Vignetti M, Tura S.

Eur J Haematol. 2014 Jun;92(6):527-36. doi: 10.1111/ejh.12300. Epub 2014 Apr 10.

PMID:
24580147
14.

Supportive care and chelation therapy in MDS: are we saving lives or just lowering iron?

Leitch HA, Vickars LM.

Hematology Am Soc Hematol Educ Program. 2009:664-72. doi: 10.1182/asheducation-2009.1.664. Review.

PMID:
20008252
15.

Adequate iron chelation therapy for at least six months improves survival in transfusion-dependent patients with lower risk myelodysplastic syndromes.

Delforge M, Selleslag D, Beguin Y, Triffet A, Mineur P, Theunissen K, Graux C, Trullemans F, Boulet D, Van Eygen K, Noens L, Van Steenweghen S, Lemmens J, Pierre P, D'hondt R, Ferrant A, Deeren D, Van De Velde A, Wynendaele W, André M, De Bock R, Efira A, Breems D, Deweweire A, Geldhof K, Pluymers W, Harrington A, MacDonald K, Abraham I, Ravoet C.

Leuk Res. 2014 May;38(5):557-63. doi: 10.1016/j.leukres.2014.02.003. Epub 2014 Feb 14.

PMID:
24661630
16.

Guidelines for treating iron overload in myelodysplastic syndromes: a Taiwan consensus statement.

Ko BS, Chang CS, Chang MC, Chen TY, Chiou TJ, Chiu CF, Huang WL, Kao WY, Lan YJ, Lin SF, Tan TD, Tang JL, Tzeng CH, Wang PN, Yet SP, Tien HF.

Int J Hematol. 2014 Jul;100(1):7-15. doi: 10.1007/s12185-014-1607-x. Epub 2014 Jun 13.

PMID:
24924953
17.

The relevance of iron overload and the appropriateness of iron chelation therapy for patients with myelodysplastic syndromes: a dialogue and debate.

Steensma DP.

Curr Hematol Malig Rep. 2011 Jun;6(2):136-44. doi: 10.1007/s11899-011-0084-z. Review.

PMID:
21373838
18.

Overview of guidelines on iron chelation therapy in patients with myelodysplastic syndromes and transfusional iron overload.

Gattermann N.

Int J Hematol. 2008 Jul;88(1):24-9. doi: 10.1007/s12185-008-0118-z. Epub 2008 Jun 27. Review.

19.

Controversies surrounding iron chelation therapy for MDS.

Leitch HA.

Blood Rev. 2011 Jan;25(1):17-31. doi: 10.1016/j.blre.2010.09.003. Epub 2010 Oct 27. Review.

PMID:
21030120
20.

Deferasirox for managing iron overload in people with myelodysplastic syndrome.

Meerpohl JJ, Antes G, Rücker G, Fleeman N, Motschall E, Niemeyer CM, Bassler D.

Cochrane Database Syst Rev. 2010 Nov 10;(11):CD007461. doi: 10.1002/14651858.CD007461.pub2. Review. Update in: Cochrane Database Syst Rev. 2014;10:CD007461.

PMID:
21069694

Supplemental Content

Support Center